Ftse Mib
33.394,02
0,30%
DAX
19.245,89
0,51%
S&P 500
5.948,71
0,53%
NASDAQ
18.972,42
0,03%
Bitcoin
99.013,22
0,51%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Cue Biopharma Inc (CUE) Cue Biopharma Inc (CUE) Notizie

Cue Biopharma Inc

CUE
1,03
0,00 (0,00%)
22 Nov 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
14/11/202422:05GLOBECue Biopharma Reports Third Quarter 2024 Financial Results..
14/11/202422:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/11/202422:00EDGAR2Form 8-K - Current report
14/11/202414:00GLOBECue Biopharma Announces Strategic Organizational Transition
12/11/202414:00GLOBECue Biopharma to Participate in Fireside Chat at the Stifel..
08/11/202419:30GLOBECue Biopharma Presents Positive Updated Data from its Phase..
08/10/202422:00EDGAR2Form 8-K - Current report
07/10/202423:07EDGAR2Form SCHEDULE 13G/A - Statement of Beneficial Ownership by..
04/10/202422:00EDGAR2Form 8-K - Current report
04/10/202415:00GLOBECue Biopharma Announces Upcoming Scientific Presentations at..
27/9/202422:17EDGAR2Form 8-K - Current report
27/9/202422:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
27/9/202405:26GLOBECue Biopharma Announces Pricing of $12.0 Million Public..
27/9/202405:10GLOBECue Biopharma Announces Proposed Public Offering
26/9/202422:32EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
26/9/202422:27GLOBECue Biopharma Announces Proposed Public Offering
10/9/202422:00EDGAR2Form DEF 14A - Other definitive proxy statements
09/9/202414:00GLOBECue Biopharma Appoints Industry Veteran Lucinda Warren as..
05/9/202422:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/9/202422:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/9/202422:30EDGAR2Form 8-K - Current report
03/9/202414:00GLOBECue Biopharma to Present at The Promise of Interleukin-2..
28/8/202422:00EDGAR2Form PRE 14A - Other preliminary proxy statements
19/8/202422:05GLOBECue Biopharma Reports Second Quarter 2024 Financial Results..
16/8/202422:00EDGAR2Form 8-K - Current report
14/8/202422:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/8/202414:00GLOBECue Biopharma to Host Business Update Call and Webcast
25/7/202422:05GLOBECue Biopharma Announces Strategic Prioritization of..
25/7/202422:00EDGAR2Form 8-K - Current report
07/6/202422:00EDGAR2Form 8-K - Current report
07/6/202422:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/6/202422:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/6/202422:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/6/202414:00GLOBECue Biopharma Presents Updated Data from Phase 1 Trial of..
03/6/202414:00GLOBECue Biopharma to Present at Two Upcoming Investor Healthcare..
24/5/202422:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
09/5/202422:05GLOBECue Biopharma Reports First Quarter 2024 Financial Results..
09/5/202422:01EDGAR2Form 8-K - Current report
09/5/202422:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/5/202414:00GLOBECue Biopharma to Present at the 20th Annual PEGS Boston..
07/5/202414:00GLOBECue Biopharma to Participate in Fireside Chat at The..
24/4/202416:01GLOBECue Biopharma to Present at the 2024 American Society of..
08/4/202422:05GLOBECue Biopharma Reports Fourth Quarter and Full Year 2023..
02/4/202414:00GLOBECue Biopharma to Host Business Update Call and Webcast
08/3/202422:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202422:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202422:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202422:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202416:00GLOBECue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured..
22/2/202422:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: Min: Max:
Chiusura: 1,03

La tua Cronologia

NASDAQ
CUE
Cue Biopharma
ASX
RF1
Regal Investment
NASDAQ
LIDRW
AEye
TSXV
NWST
Northwest Copper
USOTC
PNRLF
Premium Resources (PK)
LSE
0JKC
Ishares Silver
LSE
CLDN
Caledonia Investments
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network